search
Back to results

Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA? (CARS-1)

Primary Purpose

Arthroplasty, Replacement, Shoulder, Shoulder Osteoarthritis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
BIO-RSA
RSA
Sponsored by
Lovisenberg Diakonale Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arthroplasty, Replacement, Shoulder focused on measuring Reverse Shoulder Arthroplasty, BIO-RSA, Orthopedic surgery

Eligibility Criteria

45 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Eligible for primary RSA due to OA, massive RC tear, failed RC repair or post-instability osteoarthritis Able to read or write Norwegian Exclusion Criteria: Severe osteoporosis Osteonecrosis of the humeral head Dementia Poor deltoid function Revision surgery ASA IV Suspected chronic infection Acute fracture

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    BIO-RSA

    RSA

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change in WOOS index from baseline to 24 months postoperatively.
    The Western Ontario Osteoarthritis of the Shoulder (WOOS) index is a patient-reported, disease-specific questionnaire for the measurement of the quality-of-life in patients with osteoarthritis. There are 19 questions divided into four domains: Physical symptoms, sports and work, lifestyle and emotions. Each question is answered on a visual analogue scale ranging from 0 to 100. The overall score ranges from 0 to 1900, with 1900 being the worst. For ease of interpretation, the scores are often converted to a percentage of the maximum score.

    Secondary Outcome Measures

    Change in EuroQol-5 from baseline to 24 months postoperatively.
    The widely used EuroQol-5 (EQ-5D-5L) will be used to measure health-related quality of life. The EQ5D-5L consists of two parts: A descriptive system (Mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and the EQ-VAS that record patients self-rated health on a visual analog scale that range from 0 -100, higher levels indicate better self-rated health. The descriptive system can be converted to a single summary index number where lower levels indicate poorer health related quality of life.
    CT scan
    Assessment of bone transplant integration and fixation of the glenoid implant.
    Change in Constant-Murley Score from baseline to 24 months postoperatively.
    The Constant-Murley Score (CMS) is a multi-item functional scale assessing pain, ADL, ROM and strength of the affected shoulder. Its score ranges from 0 to 100 points, representing worst and best shoulder function, respectively. The test is divided into subjective and objective components. Two subjective: pain and activities of daily living (ADL) and two objective: range of motion (ROM) and strength. The subjective components can receive up to 35 points and the objective 65. Pain and ADL are answered by the patient; ROM and strength require a physical evaluation and are answered by the physiotherapist.
    Change in range of motion from baseline to 24 months postoperatively.
    The patient's active and passive range of motion (ROM) in the affected shoulder will be measured by an experienced physiotherapist with a long-legged goniometer. The directions measured will be flexion, abduction, external rotation and internal rotation, measured in degrees and/or physical landmarks.
    Change in Subjective Shoulder Value from baseline to 24 months postoperatively.
    The Subjective Shoulder Value (SSV) score is defined as the subjective evaluation by the patient of shoulder function, expressed as a percentage of an entirely normal shoulder, which would score 100%.
    Anchor question 1
    This anchor question is asked to help determine Patient Acceptable Symptom State (PASS). PASS "Considering all daily activities that involves your operated shoulder, your level of pain and degree of function, how satisfied are you with the condition of your shoulder is right now?" Alternatives: Satisfied/somewhat satisfied/Neither satisfied or unsatisfied/somewhat unsatisfied/Unsatisfied
    Anchor question 2
    This anchor question is asked to help determine Minimal Important Difference (MID) and Substantial Clinical Benefit (SCB). "Think of all the ways your operated shoulder has affected you the last week. Since your surgery, has there been any change in the condition of your shoulder that you would consider important or meaningful to you?" Alternatives: Much better/moderately better/a bit better/no change/a bit worse/moderately worse/Much worse.

    Full Information

    First Posted
    June 28, 2023
    Last Updated
    September 12, 2023
    Sponsor
    Lovisenberg Diakonale Hospital
    Collaborators
    Haukeland University Hospital, Sykehuset Telemark, University Hospital, Akershus
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06025331
    Brief Title
    Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?
    Acronym
    CARS-1
    Official Title
    From Cuff Arthropathy to Reverse Shoulder Arthroplasty - a Multicentre Randomized Control Trial (Study 1: Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?).
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 15, 2023 (Anticipated)
    Primary Completion Date
    August 1, 2033 (Anticipated)
    Study Completion Date
    August 1, 2033 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Lovisenberg Diakonale Hospital
    Collaborators
    Haukeland University Hospital, Sykehuset Telemark, University Hospital, Akershus

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this clinical trial is to compare two different types of reverse shoulder replacements. Researchers will compare a conventional reverse shoulder replacement with a lateralized reverse shoulder replacement to see if there is a difference in how well the patients function after two years.
    Detailed Description
    Many studies have showed pain relief and improvement in shoulder function following reverse shoulder arthroplasty (RSA), but medialization of the centre of rotation (COR) in RSA may cause complications like limited range of motion (ROM), luxation of the prosthesis, and scapular notching, where the lower part of the scapular neck becomes eroded due to impingement against the humeral component. Joint centre lateralization with a bone transplant placed underneath the glenoid component (BIO-RSA) was introduced to maximize ROM in the prosthetic joint, increase stability and to prevent scapular notching. In recent years it has been claimed that lateralization of the COR with BIO-RSA decreases the risk of the aforementioned complication, but no consensus on when or how to lateralize the COR exists as of today. This knowledge will also be of critical importance when it comes to decision making on how these patients are best treated. Results from this research project is expected to have a significant impact on how these patients are treated in the future, both nationally and internationally. The purpose of this study is to compare functional results between patients with bony increased offset-reversed shoulder arthroplasty (BIO-RSA) and conventional reverse shoulder arthroplasty (RSA) to investigate if lateralization of the glenosphere yields superior outcomes and fewer complications after 2 years. This multicenter study will include 130 patients in 4 hospitals scheduled for RSA. Patients will be asked to participate in a blinded RCT, where they are randomly assigned to either BIO-RSA or conventional RSA. Functional results will be measured primarily by the patient-reported outcome measure Western Ontario Osteoarthritis Shoulder (WOOS), but they will also be examined by a physiotherapist and CT imagery will be assessed by a radiologist.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Arthroplasty, Replacement, Shoulder, Shoulder Osteoarthritis
    Keywords
    Reverse Shoulder Arthroplasty, BIO-RSA, Orthopedic surgery

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Masking Description
    Participants and health personnel examining the participants will be blinded. It will not be possible to blind the surgeons due to the nature of the intervention.
    Allocation
    Randomized
    Enrollment
    130 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    BIO-RSA
    Arm Type
    Experimental
    Arm Title
    RSA
    Arm Type
    Active Comparator
    Intervention Type
    Procedure
    Intervention Name(s)
    BIO-RSA
    Other Intervention Name(s)
    Bony increased offset-reversed shoulder arthroplasty
    Intervention Description
    Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.
    Intervention Type
    Procedure
    Intervention Name(s)
    RSA
    Other Intervention Name(s)
    Reverse shoulder arthroplasty
    Intervention Description
    Conventional reversed shoulder arthroplasty(RSA) will be performed.
    Primary Outcome Measure Information:
    Title
    Change in WOOS index from baseline to 24 months postoperatively.
    Description
    The Western Ontario Osteoarthritis of the Shoulder (WOOS) index is a patient-reported, disease-specific questionnaire for the measurement of the quality-of-life in patients with osteoarthritis. There are 19 questions divided into four domains: Physical symptoms, sports and work, lifestyle and emotions. Each question is answered on a visual analogue scale ranging from 0 to 100. The overall score ranges from 0 to 1900, with 1900 being the worst. For ease of interpretation, the scores are often converted to a percentage of the maximum score.
    Time Frame
    Before randomization, 24 months postoperatively. Also measured 3 and 12 months postoperatively. Change after 24 months will be the primary outcome.
    Secondary Outcome Measure Information:
    Title
    Change in EuroQol-5 from baseline to 24 months postoperatively.
    Description
    The widely used EuroQol-5 (EQ-5D-5L) will be used to measure health-related quality of life. The EQ5D-5L consists of two parts: A descriptive system (Mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and the EQ-VAS that record patients self-rated health on a visual analog scale that range from 0 -100, higher levels indicate better self-rated health. The descriptive system can be converted to a single summary index number where lower levels indicate poorer health related quality of life.
    Time Frame
    Before randomization, 3, 12 and 24 months postoperatively.
    Title
    CT scan
    Description
    Assessment of bone transplant integration and fixation of the glenoid implant.
    Time Frame
    Before randomization, 3, 12 and 24 months postoperatively.
    Title
    Change in Constant-Murley Score from baseline to 24 months postoperatively.
    Description
    The Constant-Murley Score (CMS) is a multi-item functional scale assessing pain, ADL, ROM and strength of the affected shoulder. Its score ranges from 0 to 100 points, representing worst and best shoulder function, respectively. The test is divided into subjective and objective components. Two subjective: pain and activities of daily living (ADL) and two objective: range of motion (ROM) and strength. The subjective components can receive up to 35 points and the objective 65. Pain and ADL are answered by the patient; ROM and strength require a physical evaluation and are answered by the physiotherapist.
    Time Frame
    Before randomization, 3, 12 and 24 months postoperatively.
    Title
    Change in range of motion from baseline to 24 months postoperatively.
    Description
    The patient's active and passive range of motion (ROM) in the affected shoulder will be measured by an experienced physiotherapist with a long-legged goniometer. The directions measured will be flexion, abduction, external rotation and internal rotation, measured in degrees and/or physical landmarks.
    Time Frame
    Before randomization, 3, 12 and 24 months postoperatively.
    Title
    Change in Subjective Shoulder Value from baseline to 24 months postoperatively.
    Description
    The Subjective Shoulder Value (SSV) score is defined as the subjective evaluation by the patient of shoulder function, expressed as a percentage of an entirely normal shoulder, which would score 100%.
    Time Frame
    Before randomization, 3, 12 and 24 months postoperatively.
    Title
    Anchor question 1
    Description
    This anchor question is asked to help determine Patient Acceptable Symptom State (PASS). PASS "Considering all daily activities that involves your operated shoulder, your level of pain and degree of function, how satisfied are you with the condition of your shoulder is right now?" Alternatives: Satisfied/somewhat satisfied/Neither satisfied or unsatisfied/somewhat unsatisfied/Unsatisfied
    Time Frame
    Before randomization, 3, 12 and 24 months postoperatively.
    Title
    Anchor question 2
    Description
    This anchor question is asked to help determine Minimal Important Difference (MID) and Substantial Clinical Benefit (SCB). "Think of all the ways your operated shoulder has affected you the last week. Since your surgery, has there been any change in the condition of your shoulder that you would consider important or meaningful to you?" Alternatives: Much better/moderately better/a bit better/no change/a bit worse/moderately worse/Much worse.
    Time Frame
    3, 12 and 24 months postoperatively.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    45 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Eligible for primary RSA due to OA, massive RC tear, failed RC repair or post-instability osteoarthritis Able to read or write Norwegian Exclusion Criteria: Severe osteoporosis Osteonecrosis of the humeral head Dementia Poor deltoid function Revision surgery ASA IV Suspected chronic infection Acute fracture
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Kjersti Kaul Jenssen, PhD
    Phone
    +4790200650
    Email
    KjerstiKaul.Jenssen@lds.no
    First Name & Middle Initial & Last Name or Official Title & Degree
    Hanne Fuglø, MPTh
    Phone
    +4790524172
    Email
    hanne.fuglo@lds.no
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Sigbjørn Dimmen, PhD
    Organizational Affiliation
    University of Oslo
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Kjersti Kaul Jenssen, PhD
    Organizational Affiliation
    Lovisenberg Diaconal Hospital
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Christian Owesen, PhD
    Organizational Affiliation
    Lovisenberg Diaconal Hospital
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?

    We'll reach out to this number within 24 hrs